Preserve Muscle During Weight Loss? Regeneron’s COURAGE Trial Suggests a New Path with Antibody Therapy
New interim data reveals a way to counter muscle loss caused by semaglutide—Regeneron’s antibody combinations may offer a smarter weight-loss strategy focused on body composition.
Table of Contents
Regeneron’s Phase 2 COURAGE Trial: A New Strategy for Muscle-Sparing Weight Loss
The Challenge
What the COURAGE Trial Tested
- Population: Adults with obesity (BMI ≥ 30 kg/m²)
- Treatments (Phase 1, Weeks 0–26): Semaglutide alone; Semaglutide + trevogrumab, low or high dose (anti‑GDF8/myostatin); Triplet combo: Semaglutide + high-dose trevogrumab + garetosmab (anti‑activin A)
- Endpoints: At Week 26, evaluated percent change in body weight, lean mass, and fat mass via DXA (dual-energy X-ray absorptiometry).
Interim Results from Week 26
Semaglutide Alone
- Total Weight Loss: 23 lb
- Lean Mass Loss: 34.5% (~7.9 lb)
- Fat Mass Loss: 66.3%
Low-Dose Combo (Semaglutide + Low Trevogrumab)
- Total Weight Loss: 21.6 lb
- Lean Mass Loss: ~17% (~3.7 lb)
- Fat Mass Loss: 78.1%
- Lean Mass Preserved: ~50.8% vs semaglutide alone
High-Dose Combo (Semaglutide + High Trevogrumab)
- Total Weight Loss: 24.8 lb
- Lean Mass Loss: ~16.8% (~4.2 lb)
- Fat Mass Loss: 76.3%
- Lean Mass Preserved: ~51.3% vs semaglutide alone
Triplet Combo (Semaglutide + High Trevogrumab + Garetosmab)
- Total Weight Loss: 30 lb
- Lean Mass Loss: ~6.6% (~2.0 lb)
- Fat Mass Loss: 84.4%
- Lean Mass Preserved: ~80.9% vs semaglutide alone
Key insight: All combo treatments preserved significantly more lean mass and enhanced fat loss compared to semaglutide alone. The triplet group showed the strongest effect: muscle preservation of ~81% and greatest fat reduction.
Safety Signals
- General tolerability: Semaglutide + trevogrumab was similar to semaglutide alone.
- Triplet arm: Higher adverse events—28.3% discontinued, ~10% experienced severe treatment-emergent adverse events (TEAEs), including two deaths (one from cardiac arrest; no causal link established).
Why Muscle-Sparing Matters
Weight loss is only part of the story. For patients using semaglutide, a significant portion of that weight—up to 35%—can come from lean muscle. That’s not just a cosmetic concern; it’s a risk to strength, mobility, metabolic health, and long-term wellbeing.
Regeneron’s COURAGE trial offers a glimpse into a new approach: combining semaglutide with targeted antibodies to protect muscle while enhancing fat loss. Rather than settling for a lower number on the scale at the cost of strength and function, this approach opens the door to smarter, more targeted weight-loss outcomes.
Here’s what stands out:
- More providers are recognizing that how patients lose weight is just as important as how much they lose.
- The COURAGE trial addresses a persistent issue with GLP-1 therapies: unintended muscle loss.
- The study explores a novel co-therapy model where antibody-based treatments (trevogrumab and garetosmab) are layered onto semaglutide.
- Results suggest this strategy significantly boosts fat loss while protecting lean mass, improving both health outcomes and patient satisfaction.
- If confirmed safe and sustainable, this approach may reshape the standard of care for obesity—focusing on composition, not just pounds lost.
Key Takeaways for Providers
- Semaglutide alone: About 35% of weight lost is lean mass, which may undermine functional outcomes.
- Adding antibodies: Trevogrumab (anti-myostatin) with or without garetosmab (anti-activin A) preserved 51–81% more muscle and increased fat loss.
- Best balance: The triplet combo was most effective but had more safety concerns. Dual antibody regimens may offer the best balance of efficacy and safety.
- What’s next: Final phase 2 data will include results from the maintenance phase (weeks 26–52).
Who Could Benefit
- Patients on GLP-1 receptor agonists struggling with unintended muscle loss
- Individuals seeking more functional or metabolic benefits from weight loss
- Providers concerned about sarcopenia or frailty during obesity treatment
What Comes Next
- Monitor publication of full 52-week COURAGE trial data
- Evaluate long-term outcomes on both body composition and adverse events
- Prepare to integrate antibody therapies into future obesity protocols—if confirmed safe and effective
Conclusion
The interim findings from Regeneron’s COURAGE trial underscore a pivotal shift in how we think about weight loss—moving beyond just the number on the scale.
By prioritizing fat loss while preserving lean muscle, this antibody-supported approach could set a new standard for safer, more functional weight reduction.
While questions about long-term safety remain, the potential to improve patient outcomes by focusing on composition, not just weight, is worth watching as the full trial data emerges.
Online Medical Weight Management Training
GLP-1 Certification for Weight Management
Build an evidence-based foundation in GLP-1s and FDA-approved medical weight-management treatments through IAPAM’s online Certified Medical Weight Management Provider™ (CWMP) program.
Click the image to explore CWMP certification.
Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →